Abstract 3416: Advancing cancer immunotherapy: PD-L1-targeted IFNa2a fusion protein RO7694744
Moritz Rapp(Center for Integrated Protein Science Munich), Pablo Umaña(Zurich Insurance Group (Switzerland)), Martin Lechmann(Roche (Switzerland)), M Donev(Roche (Switzerland)), Davide Bertoldo, Malika Ait‐Goughoulte(Roche (Switzerland)), Martina Antoniolli(Roche (Switzerland)), K Meier(CS Diagnostics), Steffen Dettling(Heidelberg University), Kerstin Paetzold, Barbara Leutgeb(Goethe University Frankfurt), Meher Majety(Roche Pharma AG (Germany)), Andreas Roller(Roche (Switzerland)), Anja Irmisch(University of Zurich), Christian Klein(Roche (Switzerland)), N Gochitashvili(Roche (United Kingdom)), Johannes Sam(Roche (Switzerland)), Jack A. Bates, Robert M. Mader(Centre de Recherche en Économie et Management), Harald Duerr, Yan Li(Second Military Medical University), Claudia Mueller(Leipzig University), Daniela Willend(Roche (Switzerland)), Gabriel Schnetzler(Roche (Switzerland)), Laura Kruempelmann, Marina Bacac(Roche (Switzerland))
Cited by 0
Related Papers
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
|Journal of Clinical Oncology|2021|428
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes
|The Journal of Experimental Medicine|2019|275